B
Bull
Bull · 25%SYBX
$1.87
Precio del escenario
$0.560
-0.280 (-50.00%)Al cierre
Loading chart…
- High
- 0.777
- Open
- 0.777
- VWAP
- 0.63
- Vol
- 3.57M
- Mkt Cap
- 18.15M
- Low
- 0.560
- Amount
- 2.26M
- EV/EBITDA, TTM
- 0.00
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
Analyst Ratings (1)
Buy
1 Buy
0 Hold
0 Sell
Current: 0.56
Mínimo
—
Promedio
—
Máximo
—
HC Wainwright & Co.
Hold
—
2024-03-20
HC Wainwright & Co.
2024-03-20
Precio objetivo
—
Hold
HC Wainwright & Co.
Strong Sell
—
2024-02-09
HC Wainwright & Co.
2024-02-09
Precio objetivo
—
Strong Sell
Leerink Partners
Hold
$1
2024-02-09
Leerink Partners
2024-02-09
Precio objetivo
$1
Hold
Chardan Capital
Hold
—
2024-02-09
Chardan Capital
2024-02-09
Precio objetivo
—
Hold
Alliance Global Partners
Strong Buy
$30
2023-12-11
Alliance Global Partners
2023-12-11
Precio objetivo
$30
Strong Buy
Métricas de valoración
The current forward P/E ratio for Synlogic Inc (SYBX) is -2.49, compared to its 5-year average forward P/E of -1.88.
Alphio AI Price Scenarios for SYBX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding SYBX
Cronología de eventos
Noticias
SYBX FAQ — answered by Alphio AI
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
1 analysts cover SYBX: 1 rate it Buy, 0 Hold and 0 Sell.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.